Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Cell-based therapies group MaxCyte said it had entered into a development agreement with KSQ Therapeutics.
The pact would see KSQ gain rights to use MaxCyte's technology for the advancement of its engineered tumor-infiltrating lymphocyte programs, being developed for the treatment of refractory solid tumors.
In return, MaxCyte would be eligible to receive certain milestone payments in addition to other licensing fees.